KRAS and non-small cell lung carcinoma: Unfortunately, these preclinical results did not translate into an increased clinical activity (31, 32); indeed, a retrospective study conducted on 1,190 KRAS-mutant NSCLC patients treated with upfront platinum-based doublet chemotherapy has demonstrated that pemetrexed was associated with a shorter progression-free interval compared to other agents, such as taxanes (32).